503 results about "Combination drug" patented technology

Controlled quantities of powdered medication are formed in controlled release packages using electrostating metering. Also provided are combination medication therapy delivery packages comprising two or more active pharmaceuticals segregated from one another in a single delivery package.

The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and / or active circulating glucagon-like peptide-2 (GLP-2).

The present invention relates to liquid sustained release suspension dosage forms. In particular, the invention encompasses sustained release compositions comprising a dispersed phase, which contains an ion-exchange matrix drug complex, a diffusion controlling membrane coating and a dispersion medium comprising an excipient capable of impeding water activity such that drug dissolution is inhibited prior to administration. Further, the invention provides for compositions wherein several active ingredients associate in a single bead in the dispersed phase, such that the abuse potential of such active ingredients is reduced. The invention also encompasses sustained release formulations of combination drugs comprising an extended release phase and an immediate release phase. The formulations of the invention may be used to treat a variety of conditions and symptoms, including those that require administration of several drugs, such as cold and allergy symptoms. In one of the embodiments, the sustained release composition combines an antihistamine, an antitussive and a decongestant. The invention further provides for methods of making and using such formulations.

This patent is an evolution of previous combination medication patents. Previous combination patents such as U.S. Pat. No. 6,613,354 which is a combination of an NSAID and Proton Pump Inhibitor. Thus the previous patents have covered gastrointestinal prophylaxis but none has covered both gastrointestinal and cardiovascular prophylaxis. This is likely because the cardiovascular side effects of NSAIDs were only recently discovered. This patent thus represents a leap in safety in a class of medication that is used by millions of Americans on a daily basis. This combination would thus decrease morbidity and mortality.

Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalation particles of the invention are particularly useful in the administration of a combination medicament, e.g. a combination of an anti-inflammatory agent and a bronchodilator, by inhalation in the treatment of asthma and other respiratory disorders.

The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with other preventive or therapeutic drug for glaucoma or ocular hypertension, their intraocular pressure lowering effects are complemented and / or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.

This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

The invention provides block polymers, micelles, and micelle formulations for combination drug therapy. Polyamide block polymers, such as those of formulas I and II are useful, for example, for preparation of mixed drug micelles, including simply mixed micelles, physically mixed micelles, and chemically mixed micelles. The invention further provides methods of treating cancer, and inhibiting and killing cancer cells. Also provided are methods for the preparation of polymer drug conjugates and intermediates for their synthesis.

A modified release dosage product (5) comprises a plurality of minicapsules or minispheres (1, 2) containing nimodipine, and a plurality of minicapsules or minispheres (3), (4) containing tacrolimus. There are uncoated minicapsules or minispheres (1) encapsulating micronized nimodipine for immediate release and a controlled release polymer coated minicapsule or minisphere (2) encapsulating micronized nimodipine for delayed, sustained, controlled or targeted release. There are uncoated seamless minicapsules (3), the core of which comprises tacrolimus lipid-based formulation for immediate release and a controlled release polymer coated seamless minicapsule (4), the core of which comprises tacrolimus lipid-based formulation for delayed, sustained, controlled release or targeted release. The final dosage form may be a hard gelatin capsule (5).

Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.

The present invention relates to a functional combination preparation comprising a dihydropyridine-based calcium channel blocker such as amlodipine and an ARB (Angiotensin-2 receptor blocker) such as losartan. In particular, the present invention relates to a chronotherapeutical combination pharmaceutical formulations with controlled-release for the prevention or treatment of cardiovascular disease, which is formulated in accordance with xenobiotics and chronotherapy for enabling the two drugs to be chronotherapeutically released, thereby improving the therapeutic activity as compared to the co-administration of each drug in the form of a single pill, while reducing side effects and maintaining the therapeutic activity as high as possible at the time of day when the risk of a complication of cardiovascular disease is highest.

A combination drug therapy can be administered to patients to treat xerostomia or dry mouth or Sjogren's syndrome in the form of orally dissolving film or orally disintegrating tablets. Some of the drugs could be synthetic origin and some drugs are obtained from natural sources.

A home pharmacy kit provided to organize, educate, simplify and add convenience to the consumer regarding self-treatment with over-the-counter (OTC) drugs and self-management of therapy with widely and commonly used OTC medications. The kit of the invention allows a consumer to achieve appropriate therapy when self-medicating and allows a consumer to avoid therapeutic duplication and over utilization and / or underutilization of medications, which may result from a lack of consumer related to the action and effects of common active ingredients found in a wide variety of cold and cough combination drug products as well as in gastrointestinal combination drug products.

A co-crystal composition comprised of Quercetin and at least one antidiabetic agent acts as a combination drug having unique physical properties and biological activity, which differ from both Quercetin in pure form and the at least one antidiabetic agent in pure form. The co-crystal composition may comprise quercetin and metformin. The co-crystals of quercetin and metformin may be prepared by grinding the compounds, and used in pharmaceutical compositions comprising these co-crystals. Co-crystal compositions of quercetin and Metformin may be used in combination with other anti-diabetic agents, including DPP-IV inhibitors.

The invention relates to a combination drug used in the gastroscopy, in particular to a combination drug comprising dimethicone emulsion or simethicone emulsion and analgesics or local anesthetics and a preparaiton method thereof. The combination drug of the invention is mainly prepared by the following raw materials of 0.1wt percent to 5wt percent of analgesics or local anesthetics, 1wt percent to 40wt percent of dimethicone emulsion / simethicone emulsion, 0.1wt percent to 8wt percent of emulsifier, 0wt percent to 20wt percent of thickening agent, 0.01wt percent to 0.5wt percent of antibacterial agent and 27wt percent to 98wt percent of pure water. Compared with the prior art, in the preparation of the invention, the dimethicone emulsion / the simethicone emulsion is scattered and emulsified into liquid drops which have the particle size of about 300nm, large specific surface area, short defoaming time and good effects; liquid drops with the nano size scattered and emulsified by the dimethicone emulsion / the simethicone emulsion have good stability without oil leak, dispersion, etc., when in storage for a long term.

The invention belongs to the field of medicine and biotechnology, and relates to a synergistic drug compound for treating tumors and a preparation method thereof. The drug compound is composed of one or more cell autophagy inhibitors and arginase, especially human recombinant Arginase is made into a synergistic drug compound for treating tumors, and the synergistic drug compound can inhibit autophagy by inhibiting autophagy through autophagy inhibitors to increase tumor cells' ability to arginase. sensitivity, and enhance the therapeutic effect of arginase, especially human recombinant arginase, on tumors, especially triple-negative breast cancer cells. The drug compound of the present invention can be used for clinical treatment of breast cancer, melanoma, lung cancer, brain tumor, lymphoma, leukemia and myeloma.

A system and method for determining an optimal combination drug product for a particular patient includes a processor that receives patient information and determines an optimal combination drug product based on the received information. A system which can provide information regarding predicted events or pathologies based on received patient information and guidance on subsequent steps to ameliorate, treat or intervent. A drug production device includes a plurality of drug containers, each of which are coupled to a drug dispensing channel. A controller controls the dispensing of drug through each channel, and a combination drug product is produced from the dispensed drugs. A combination drug product includes a plurality of discrete units of a first drug, and a plurality of discrete units of a second drug.; A transdermal patch includes a plurality of drug compartments, each containing a quantity of drug product, and a controller for controlling the release of drugs from each compartment. Feedback loop elements can enable iterations to optimized personalized doses.

Combination medicine containers and dispensers are shaped similar to or generally the same as standard prescription medicament containers but are configured to dispense one medicament at a time through easy manipulation of integral dispensing means. Each combination medicine container and dispenser has a bottle, a cap, and an integral dispensing mechanism that cooperate with one or more structures of the bottle and / or cap to dispense one medicament at a time from the container. In one form, the combination medicine container and dispenser is designed to allow a user to dispense a single medicament through properly applied pressure. In another form, rotation of one or more components provides dispensing of a single medicament.

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and / or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

The invention provides a drug delivery system for a combination of therapeutic agents. The system includes a water soluble biodegradable ABA-type triblock copolymer that possesses thermosensitive gelation properties. The system can form a stable thermogel that includes a combination of therapeutic agents including, for example, rapamycin, paclitaxel, and 17-AAG. After administration to a subject, the drugs are released at a controlled rate from the thermogel, which biodegrades into non-toxic components. The polymer system can also function to increase the solubility and stability of drugs in the composition.

An antitumor agent for chemoradiotherapy of rectal cancer comprising a combination of TS-1 (a combination drug of tegafur, gimeracil, and oteracil potassium at a 1:0.4:1 molar ratio) and CPT-11 (irinotecan hydrochloride). The antitumor agent of the invention can achieve marked tumor volume reduction without causing major side effects, especially by coadministering it with preoperative radiation therapy. The volume of even large tumors that are refractory to surgical resection can be reduced by coadministering the antitumor agent of the invention with preoperative radiation therapy, making the subsequent surgical resection of the tumor easier.

A combined composition comprising an anti-4-1BB monoclonal antibody and chemotherapeutic anti-cancer agent for preventing and treating cancer disease. Provides a pharmaceutical composition comprising the combined mixture of anti-4-1BB antibody and chemotherapeutic anti-cancer agent enhancing the specific immune response to cancer and killing cancer cell for treating or preventing cancer disease as an effective ingredient, together with a pharmaceutically acceptable carrier.

A combination oral liquid formulation of melatonin with a antihistaminic drug has been proposed as a sleep-aid agent. The solubility and stability of melatonin was improved by using cyclodextrin and adjusting the pH to a suitable value. The combination drug is expected to have a dual mode of action. The antihistaminic agent may help patient to fall asleep quickly and melatonin may be effective subsequently providing a sound sleep to the patient.

The invention discloses a combination drug for the treatment of colds, coughs and acute and chronic bronchitis and a preparation method thereof. The combination drug includes twenty six medicines, which are ephedra vulgaris, ligusticum chuanxiong hort, angelica, stemona, white mustard seed, shizandra, liquorice, biond magnolia flower, dried orange peel, pinellia tuber, perilla fruit, balloon flower, ligusticum, peppermint, radix peucedani, common coltsfoot flower, pepper, epimedium, raidx astragali, Dangshen, dried ginger, herb of fortune eupatorium, common rush, mulberry root bark, radix bupleuri and asarum. The preparation method is as follows: volatile oil is extracted from radix bupleuri, pepper, peppermint, biond magnolia flower, ligusticum chuanxiong hort, angelica, radix peucedani, asarum and ligusticum by steam distillation, and the distillate is collected in another container; after distillation, the water solution, dregs and other ingredients are decocted for three times after being added with water, the decoction solution is mixed and filtered, the filtered solution is concentrated into clear plaster, ethyl alcohol is added until the amount of alcohol reaches 65 percent, and the mixture is mixed uniformly, frozen and filtered, the ethyl alcohol is recycled, the filtered solution is concentrated again, the ethyl alcohol is added until the amount of alcohol reaches 75 percent, and then the solution is mixed well, frozen and filtered, the ethyl alcohol is recycled until the filtered solution has no smell of alcohol, and the drug is obtained.

The invention discloses a combination drug recognition and ranking method based on a medical literature database. First, public medical literature abstracts in the medical literature database are captured, and drug entities in the medical literature abstracts are recognized; then, a feature extraction method in text mining is used for extracting features, a classification algorithm in machine learning is used for classifying drugs, and parameters of the classification algorithm are optimized through an optimization algorithm; last, Medrank is used for performing combination drug ranking to obtain a combination drug use recommendation scheme related to a certain disease. According to the combination drug recognition and ranking method, the problem that medical researchers cannot read and discover the law in mass medical literature which is increased at an exponential order every year is solved through the text mining technology and machine learning related knowledge, the ranking result of combination drugs for treating a certain disease and the variation trend over the years in the literature can be quickly known, and therefore the pressure on the medical researchers reading the mass literature is relieved.

The invention provides compounds of a novel kinase inhibitor as shown in the formula (I) or pharmaceutically acceptable salts, solvates, esters, acids, metabolites, combination drugs or prodrugs thereof. The compounds independently combines with at least one variety of other therapeutic agents and can be used to prevent or treat illnesses, disorders or diseases, and autoimmune diseases which are regulated by tyrosine kinase activity or affected by the tyrosine kinase activity or related to the tyrosine kinase activity, and specifically cancers and other cellular proliferative diseases.

A combination pharmaceutical preparation including two different active drugs of the same ionic charge conjugated with a single resin particle, without one significantly displacing the other, and without retarding the initial availability of either active. Also, methods for the manufacture of a multiple active drug-resin conjugate, and for the in vivo release of a combination of pharmaceutically active drugs from a multiple active drug-resin conjugate.

The invention provides a combination pharmaceutical composition comprising a) at least one activated-potentiated form of an antibody to at least one cytokine or at least an activated-potentiated form of an antibody to at least one receptor; and b) an effective amount of a nucleoside reverse transcriptase inhibitor, wherein said at least one cytokine or at least one receptor is participating in the regulation of immune process. Various embodiments and variants are contemplated.The invention also provides a method of treatment or prophylaxis of HIV, including AIDS, which includes administration of the combination pharmaceutical composition described in the specification to the patient in need thereof.

A combination drug treatment for inhibiting stenosis or restenosis is disclosed. The combination treatment is an active component containing both an anti-inflammatory substance and an anti-thrombotic substance which, together, contribute to an inhibiting effect on the initial stages of stenosis or restenosis. The active component can be delivered to a site of treatment by being carried on a device, such as a stent.

An object of the present invention is to further enhance the antitumor effect when oxaliplatin is administered in combination with a combination drug containing tegafur, gimeracil and oteracil potassium. According to the present invention, by using oxaliplatin encapsulated in a liposome preparation, combination therapy of oxaliplatin plus a combination drug containing tegafur, gimeracil and oteracil potassium, is revealed to show remarkably enhanced antitumor effect without increasing side effects.